Inquiry Basket
Loading ......
Chlamydia is a common sexually transmitted infection (STI) caused by bacteria. It's caused by a type of bacteria called Chlamydia trachomatis. Chlamydia trachomatis (Ct) urogenital infection is the most common bacterial sexually transmitted infection (STI) in the United States, with 1.8 million cases reported in 2018, a 19% increase since 2014. Sexually transmitted genital infection and associated disease is caused by C. trachomatis serovars D-K. In women, Ct infection can spread from the cervix into the uterus and fallopian tubes, causing inflammation and serious reproductive complications. In contrast, urethral Ct infections in men usually elicit local inflammation and self-limiting urethritis symptoms and only rarely cause upper genital tract complications.
The immunologic response to C trachomatis infection appears to play a major role in inducing immunopathology as well as in providing immune protection. One important determinant of immunity is the 40-kDa major outer membrane protein (MOMP), which induces both neutralizing antibody and T cell-mediated immune responses. Antibody to MOMP neutralizes chlamydial infectivity, both in cell cultures and in animal models. Another determinant of immunity is the C. trachomatis 60-kDa heat-shock protein (Chsp60). This protein, a member of the Gro-E1 family, exhibits ∼50% homology with human heat-shock proteins. Thus, an immune response initiated by chlamydial infection may result in cross-reactivity with human cells and tissues. This may be one mechanism through which Chlamydia-induced immune responses may ultimately be detrimental.
Fig 1. Infection of the female genital tract with Chlamydia trachomatis
(Source：Nature Reviews, 2005, 02）
Chlamydia trachomatis elementary bodies infect the columnar epithelial cells of the cervix, which often causes few or no clinical symptoms. The bacteria can ascend to infect the endometrium and the fallopian tubes, causing pelvic inflammatory disease, tubal inflammation (also known as salpingitis), scarring and occlusion, which can lead to infertility or ectopic pregnancy. The inflammatory reaction is characterized by an influx of macrophages and neutrophils and the formation of immune inductive sites in the submucosa. These inductive sites, which contain B cells, T cells, dendritic cells and macrophages, coordinate the initiation of an acquired immune response, including the deployment of a secretory IgA (sIgA) response. pIgA, polymeric IgA.
Evidence from animal models, human epidemiological studies, and early trachoma vaccine trials suggest that a C. trachomatis vaccine is feasible. Vaccine development for genital chlamydial infection has been in the preclinical phase of testing for many years, but the first Phase I trials of chlamydial vaccine candidates are underway, and scientific advances hold promise for additional candidates to enter clinical evaluation in the coming years. A major focus is development of vaccines prepared with C. trachomatis MOMP.
References
| Target | Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Sample | |
| C. Trachomatis | DEIA-CL034 | Chlamydia Trachomatis IgG ELISA Kit | 96T | Human | Quantitative | Serum, plasma | Inquiry |
| DEIA-CL035 | Chlamydia Trachomatis IgM ELISA kit | 96T | Human | Qualitative | serum, plasma | Inquiry | |
| DEIA04885 | Chlamydia trachomatis IgA ELISA Kit | 96T | Human | Quantitative | serum, plasma | Inquiry |
Loading ......
